← Back to Home

A New Option After Chemotherapy and Immunotherapy: FDA Grants Accelerated Approval to Rybrevant Faspro for Head and Neck Cancer

A dual-targeting antibody offers a later-line treatment option for some patients with recurrent or metastatic head and neck cancer. In a trial of 102 patients, 42% experienced tumor shrinkage, but whether it can prolong survival remains for confirmatory research to establish.

By SURL BioNews

When platinum-based chemotherapy and immunotherapy have both failed to stop head and neck cancer from progressing, options for the next step are often limited. On November 5, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Rybrevant Faspro, giving some patients with recurrent or metastatic head and neck squamous cell carcinoma another treatment option that uses a dual-targeting antibody to control the disease.

The approval has clear limits: it applies to adult patients whose disease has progressed after platinum-based chemotherapy and an anti-PD-1 or anti-PD-L1 antibody; human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma is excluded from the indication. The approval therefore cannot be broadly described as applicable to all advanced head and neck cancers.

Rybrevant Faspro combines amivantamab and hyaluronidase and is administered by subcutaneous injection. Amivantamab is a bispecific antibody that recognizes both EGFR and MET, aiming to interfere with the growth signals received by cancer cells; hyaluronidase helps deliver the drug through subcutaneous tissue. This strategy brings two signaling targets within the scope of a single antibody's activity.

The approval was based on the first cohort of the phase 1b/2 OrigAMI-4 trial. This multicenter, open-label study enrolled 102 patients who had received the treatments described above. The overall response rate, assessed by blinded independent central review, was 42%, with a 95% confidence interval of 32% to 52%. Johnson & Johnson also reported that 15% of patients achieved a complete response, meaning that tumor lesions disappeared according to imaging assessment criteria.

How long responses last is also central to the treatment's value. The FDA stated that, among those who responded to treatment, 56% had responses lasting at least six months; the denominator for this percentage is the responders, rather than all 102 patients. A complete response also does not mean a cure, and tumor shrinkage observed in a single-arm study does not yet establish that the drug prolongs survival more than other therapies.

Alongside the efficacy signal, the risks also need to be weighed. Trial safety data released by Johnson & Johnson showed that serious adverse reactions occurred in 39% of patients and fatal adverse reactions in 6%. The warnings listed by the FDA cover hypersensitivity and administration-related reactions, interstitial lung disease or pneumonitis, dermatologic adverse reactions, ocular toxicity, and embryo-fetal harm. These risks mean that the new option still carries a treatment burden that cannot be overlooked.

Accelerated approval gives patients earlier access to the drug while leaving evidence gaps that must be filled. Johnson & Johnson said that continued approval for this indication may depend on whether the phase 3 OrigAMI-5 confirmatory trial verifies clinical benefit. That study evaluates amivantamab combined with carboplatin and pembrolizumab as first-line treatment, a different setting from the later-line monotherapy approved here. The next key question is whether the tumor responses seen so far can translate into more durable improvements that are meaningful to patients' lives and survival.

References

  1. FDA
  2. Johnson & Johnson
  3. FDA
  4. OncLive